The cellular senescence-metabolism axis: emerging insights into T cell dynamics in the context of biological aging
Garza-Martínez L., Fitzgerald-Bocarsly P.
Narrative Review, published in Cell Commun Signal (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Cell Commun Signal (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41366437
- PMCID
- PMC12801898
- DOI
- 10.1186/s12964-025-02525-0
Abstract (original English)
The exponential growth of immunometabolism-related studies in the last 10 years has made it very clear that metabolism is a key player in the effector functions of immune cells. Such is the case in cells with lymphoid origin, as CD4 + and CD8 + T cells undergo a series of metabolic reprogramming steps during their differentiation process, which is associated with a change in their effector characteristics. Only recently have factors such as biological aging and cellular senescence been examined in relation to memory T-cell generation and the metabolic reprogramming that accompanies their differentiation. In this review, we examine the emerging roles of cellular senescence and biological aging in shaping T-cell metabolism and immune function, and how these changes in the T-cell landscape contribute to disease onset. We then discuss recent studies on T-cell metabolic reprogramming to highlight how understanding the impact of senescence on T-cell metabolism may reveal new therapeutic opportunities.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.